IL-4 Protein, Human

IL-4 Protein is an endogenous agonist of IL-4 receptor (IL-4R), which works through the JAK1/JAK3-STAT6 signaling pathway. It can cooperate with SCF to promote the proliferation of human intestinal mast cells (ED50=100 pg/mL) and enhance the release of mediators such as histamine mediated by IgE receptor. IL-4 Protein can inhibit the production of IL-8 by human monocytes and regulate the secretion of endothelial cell factors. It is mainly used for IL-4R targeted therapy research of tumors (such as malignant pleural mesothelioma) and allergic diseases. IL-4 Protein, Human is a recombinant protein of human IL-4, expressed by E. coli, with tag free.

IL-4 Protein is a cytokine of the interleukin-4 family, a glycoprotein with an α-helical structure, and an endogenous agonist of the IL-4 receptor (IL-4R), binding to the IL-4Rα and γc chains. IL-4 Protein was originally called B cell growth factor BSF1 and was described in the supernatant of activated EL-4 thymoma cells to costimulate with subservient concentrations of anti-IgM. IL-4 Protein exerts biological activity through the JAK1/JAK3-STAT6 signaling pathway, and can promote the proliferation of human intestinal mast cells (ED₅₀=100 pg/mL) in coordination with stem cell factor (SCF), enhance the release of histamine, leukotriene C₄, and IL-5 mediated by IgE receptors, inhibit the secretion of IL-8 mRNA and protein by human monocytes stimulated by LPS/TNF-α/IL-1β, and selectively enhance the secretion of IL-6 and inhibit IL-8 by human umbilical vein endothelial cells. Its mechanism of action involves regulating the expression of cell membrane receptors and the activation of downstream transcription factors. It is mainly used in the study of immune regulation mechanisms and targeted therapy of allergic diseases (such as asthma) and tumors (such as malignant pleural mesothelioma), especially the application of IL-4R-targeted cytotoxin fusion proteins (such as IL-4-PE, cpIL-4-PE) in tumor ablation. IL-4 Protein plays an important role in regulating inflammation and immune response. IL-4 Protein induces naive helper T cells to differentiate into Th2 cells. While IL-4 Protein binds to the IL-4 receptor, the IL-4 receptor also binds to another cytokine, IL-13, which may explain the overlapping functions of IL-4 and IL-13^{[1][2][3][4][5]}.

The cell proliferation assay using TF-1 human erythroleukemic cells has an ED₅₀ value of ≤450 pg/mL.

• 
  Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.The ED₅₀ for this effect is 0.2989 ng/mL., corresponding to a specific activity is 3.35×10⁶ U/mg

Human

E. coli

Tag Free

P05112-1 (H25-S153)

3565  [NCBI]

Full Length of Isoform-1 Mature Protein

HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSS

Approximately 13-15 kDa, based on SDS-PAGE under reducing conditions.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

1.Lyophilized from a 0.22 μm filtered solution of 20 mM Tris-HCl, 150 mM NaCl, pH 7.2.
2.Lyophilized from a 0.22 μm filtered solution of 50 mM Tris-HCl, 300 mM NaCl, pH 8.0.
3.Lyophilized from a 0.22 μm filtered solution of 50 mM Tris-HCl, 300 mM NaCl, pH 8.0, 5% trehalose.
4.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
Please refer to the lot-specific COA for specific buffer information.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Bischoff SC, et al. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8080-5.  [Content Brief]

  [2]. Standiford TJ, et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol. 1990 Sep 1;145(5):1435-9.  [Content Brief]

  [3]. Chen C C, et al. TGF-β1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. cytokine, 1996, 8(1): 58-65.

  [4]. Ishige K, et al. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer. 2008 Dec 15;123(12):2915-22.  [Content Brief]

  [5]. Beseth BD, et al. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg. 2004 Aug;78(2):436-43; discussion 436-43.  [Content Brief]